Publications by authors named "Tomobumi Kotani"
Article Synopsis
- Extremely low levels of alanine aminotransferase (ALT) in patients with atrial fibrillation (AF) may indicate underlying issues like aging, malnutrition, and frailty, but the connection to mortality rates hasn't been well studied.
- In a study involving over 3,000 patients with nonvalvular AF, those with very low ALT levels (≤15 U/L) were older and had worse health markers, including lower BMI and higher rates of heart failure.
- During follow-up, patients in the lowest ALT group experienced significantly higher rates of cardiovascular and all-cause mortality, highlighting low ALT as a potential indicator of higher mortality risk in AF patients, even after accounting for other health factors.
Background: In the Japanese clinical setting, the prevalence, potential cofounders of gastrointestinal (GI) bleeding from anticoagulant therapy, including direct oral anticoagulants (DOACs) and warfarin, and prognosis after GI bleeding are unclear.
Methods and results: We examined about GI bleeding from anticoagulant therapy using data from the SAKURA AF Registry, a prospective multicenter registry in Japan. Among 3,237 enrollees, 48.
Atrial fibrillation (AF) and heart failure (HF) often coexist. The aims of this study were to explore the factors associated with the serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), and the association between prognosis and a history of HF or the serum NT-proBNP level in Japanese patients with AF.The present sub-study was based on the SAKURA AF Registry, a Japanese multicenter observational registry that included 3267 AF patients (median follow-up period: 39 months).
View Article and Find Full Text PDFBackground: Liver diseases drive the development and progression of atrial fibrillation (AF). The Fibrosis-4 (FIB4) index is a non-invasive scoring method for detecting liver fibrosis, but the prognostic impact of using it for AF patients is still unknown. Herein, we evaluated using the FIB4 index as a risk assessment tool for cardiovascular events and mortality in patients with AF.
View Article and Find Full Text PDFBackground: The burden or benefit of anticoagulation treatment affects patient satisfaction, which may in turn affect the adherence to the treatment and subsequent outcomes. Thus, we hypothesized that the patient satisfaction with direct oral anticoagulants (DOACs) may influence the clinical outcome in patients with atrial fibrillation (AF).
Methods And Results: We investigated the clinical outcomes among 719 DOAC users (age 71.
Background: Atrial fibrillation (AF) and chronic kidney disease (CKD) often coexist, but the real-world data after approval of direct oral anticoagulants (DOACs) are still lacking in Japan. We investigated the association of the baseline renal function and adverse clinical events and risk of adverse clinical events with DOACs compared to warfarin for each renal functional level in Japanese AF patients.
Methods: The present substudy was based on the SAKURA AF Registry, a Japanese multicenter observational registry (median follow-up period: 39 months).
Article Synopsis
- Atrial fibrillation (AF) and coronary artery disease (CAD) are on the rise in Japan, but there’s limited information on how these conditions affect patient outcomes in this population.
- The SAKURA AF Registry study included 3,237 patients, revealing that those with CAD experienced significantly higher rates of cardiovascular events and all-cause mortality compared to those without CAD, although stroke rates were similar.
- Use of direct oral anticoagulants (DOACs) resulted in a significantly lower risk of major bleeding among CAD patients compared to warfarin, indicating that careful management is essential for AF patients with CAD, with DOACs being preferable.
Background: Relations between characteristics and outcomes of patients in Japan with atrial fibrillation (AF) and the type of medical facility providing their outpatient care are unclear.
Methods And Results: We compared patient characteristics and outcomes between 2 university hospitals (n=1178), 20 general hospitals (n=1308), and 41 private clinics (n=751) (follow-up: 39.3 months) in the prospective SAKURA AF Registry.
To explore factors related to changing renal function and the prognostic effect of worsening renal function in patients with atrial fibrillation (AF). The present substudy was based on the SAKURA AF Registry, a Japanese multicenter prospective observational registry that includes 3267 AF patients from 63 institutions in the Tokyo area. Worsening renal function was defined as an estimated glomerular filtration rate (eGFR) decrease equaling more than 20% of the patient's baseline eGFR.
View Article and Find Full Text PDFDirect-acting oral anticoagulants (DOACs) are widely used in aged Japanese patients with atrial fibrillation (AF), but outcome data for such patients are limited. We compared outcomes between 1895 (58.5%) patients aged < 75 years (non-elderly), 1078 (33.
View Article and Find Full Text PDFBackground: Off-label dosing of direct oral anticoagulants (DOACs) is encountered clinically among patients with atrial fibrillation (AF), although data on the clinical outcomes of over- and under-dosing are lacking in Japan.
Methods and results: We examined the clinical outcomes of off-label DOAC dosing using the SAKURA AF Registry, a prospective multicenter registry in Japan. Among 3,237 enrollees, 1,676 under any of the 4 DOAC regimens were followed up for a median of 39.
Article Synopsis
- A study in Japan compared death rates and causes among patients with atrial fibrillation treated with direct oral anticoagulants (DOACs) and warfarin, involving 3267 patients monitored over 2-4 years.
- The research found no significant difference in overall mortality between the two medication groups, and most deaths were attributed to cardiac issues, cancers, or respiratory infections.
- Key factors influencing mortality included age, heart failure, renal dysfunction, and patient characteristics like sex and weight, highlighting the need for comprehensive management strategies for atrial fibrillation.
The burden of anticoagulation treatment affects patient satisfaction, which in turn affects adherence to treatment. Thus, we must thoroughly understand the advantages of direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs)/warfarin given for stroke prevention in patients with atrial fibrillation (AF). We compared satisfaction with anticoagulation therapy between 654 DOAC and 821 warfarin users enrolled in the SAKURA AF Registry.
View Article and Find Full Text PDFArticle Synopsis
- A study called the SAKURA AF Registry analyzed the effects of direct oral anticoagulants (DOACs) versus warfarin on Japanese patients with atrial fibrillation (AF) using data from 3,237 participants over a median follow-up of 39.3 months.
- Results showed no significant differences in rates of stroke or systemic embolism, major bleeding, and all-cause mortality between DOAC and warfarin users, although DOACs had a lower incidence of major bleeding.
- The high follow-up rate of the study provided reliable insights, indicating that both anticoagulant types have comparable efficacy for stroke prevention, but DOACs may offer a safer profile regarding bleeding risks.
Background: Large-scale investigations on the use of oral anticoagulants including direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) have not included Japanese patients.
Methods: We established the multicenter SAKURA AF Registry to support prospective observational research on the status of anticoagulation treatment, especially with DOAC, for AF in Japan. We enrolled 3266 AF patients treated with warfarin (=1577) or any of 4 DOACs (=1689) from 63 institutions (2 cardiovascular centers, 13 affiliated hospitals or community hospitals, and 48 private clinics) in the Tokyo area.